

# Anti-ANGPTL3 (Evinacumab), Human IgG4 Antibody

07/20

---

**CATALOG NO.:** A2171-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is an investigational human monoclonal antibody that targets angiotensin-like 3 inhibitor (ANGPTL3). ANGPTL3 is primarily expressed in the liver and it inhibits LPL activity and endothelial lipase activity. This prevents the clearance of lipids and raises the concentration of triglycerides and LDL-C in the blood. The antibody binds with high affinity and specificity to ANGPTL3 and reverses the inhibitory action on LPL, thus promoting the clearance of LDL-C from the blood. The original drug was awarded breakthrough therapy designation by the FDA to treat patients suffering from homozygous familial hypercholesterolemia (HoFH).

**ALTERNATE NAMES:** REGN 1500, REGN1500, ANL3, ANG-5, FHBL2, ANGPT5

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG4, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human ANGPTL3

**CAS NUMBER:** 1446419-85-7

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-PCSK9 (Alirocumab), Human IgG1 Antibody (A2153)  
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)  
 Anti-PCSK9 (Evolocumab), Human IgG2 Antibody (A2168)  
 Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibody (A2139)  
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)

**FOR RESEARCH USE ONLY! Not to be used on humans.**